Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b, Open Label, Dose Escalation Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of Axitinib (Ag-013736) In Combination With Crizotinib (Pf-02341066) In Patients With Advanced Solid Tumors

Next Previous
Trial Profile

A Phase 1b, Open Label, Dose Escalation Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of Axitinib (Ag-013736) In Combination With Crizotinib (Pf-02341066) In Patients With Advanced Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Axitinib (Primary) ; Crizotinib (Primary)
  • Indications Adenocarcinoma; Adrenal cancer; Advanced breast cancer; Bladder cancer; Carcinoma; Colorectal cancer; Head and neck cancer; Liver cancer; Lung cancer; Non-small cell lung cancer; Pancreatic cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Pfizer

    • Most Recent Events

    • 15 Nov 2019 Status changed from active, no longer recruiting to completed.
    • 20 Jun 2019 Planned End Date changed from 31 Jul 2018 to 30 Aug 2019.
    • 06 Jun 2017 Results (n=37; as of Aug 5, 2016), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top